AP Pharma appoints Ardea's Quart and Davis to board
This article was originally published in Scrip
Specialty pharmaceutical company AP Pharma has appointed Dr Barry Quart and Stephen Davis, both members of Ardea Biosciences' executive management team, to its board of directors. Dr Quart has been president, CEO and a director of Ardea Biosciences (recently acquired by AstraZeneca; scripintelligence.com, 23 April 2012) since its founding in 2006. Mr Davis has been Ardea's executive vice-president and chief operating officer since April 2010, and was previously CEO and a director of Neurogen.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.